Copanlisib in patients with relapsed or refractory follicular lymphoma.

被引：4
|
作者：
Dreyling, Martin H.
Santoro, Armando
Leppa, Sirpa
Demeter, Judit
Follows, George
Lenz, Georg
Kim, Won Seog
Mollica, Luigina
Nagler, Arnon
Diong, Colin Phipps
Provencio, Mariano
Stevens, Don A.
Trevarthen, David
Magagnoli, Massimo
Cupit, Lisa
Yin, Shuxin
Hiemeyer, Florian
-Vargas, Jose E. Garcia
Childs, Barrett H.
Zinzani, Pier Luigi
机构：
[1] Univ Hosp LMU, Munich, Germany
[2] Humanitas Clin & Res Ctr, Humanitas Canc Ctr, Rozzano, Italy
[3] Helsinki Univ Cent Hosp, Canc Ctr, Helsinki, Finland
[4] Semmelweis Univ, Div Haematol, Dept Internal Med 1, Budapest, Hungary
[5] Cambridge Univ Hosp, Cambridge, England
[6] Munster Univ Clin, Translat Oncol Med Clin, Munster, Germany
[7] Sungkyunkwan Univ, Div Hematol & Oncol, Samsung Med Ctr, Sch Med, Seoul, South Korea
[8] Hop Maison Neuve Rosemont, Montreal, PQ, Canada
[9] Chaim Sheba Med Ctr, Div Hematol, Tel Hashomer, Israel
[10] Singapore Gen Hosp, Dept Haematol, Singapore, Singapore
[11] Univ Autonoma Madrid, Hlth Res Inst, Hosp Univ Puerta Hierro, Madrid, Spain
[12] Norton Canc Inst, Louisville, KY USA
[13] Comprehens Canc Care & Res Inst, Englewood, CO USA
[14] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA
[15] Bayer AG, Div Pharmaceut, Berlin, Germany
[16] Univ Bologna, Inst Hematol L eA Seragnoli, Bologna, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.7535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7535
引用
收藏
页数：5
相关论文
共 50 条
  • [41] A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Crombie, Jennifer L.
    Kim, Austin I.
    Bartlett, Nancy L.
    Redd, Robert A.
    Patterson, Victoria
    Carey, Celeste
    Balasubramanian, Sobana
    Odejide, Oreofe O.
    Merryman, Reid W.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Fisher, David C.
    Herrera, Alex F.
    Davids, Matthew S.
    Shipp, Margaret A.
    Armand, Philippe
    Shouse, Geoffrey P.
    BLOOD, 2023, 142
  • [42] Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
    Merryman, Reid W.
    Redd, Robert A.
    Freedman, Arnold S.
    Ahn, Inhye E.
    Brown, Jennifer R.
    Crombie, Jennifer L.
    Davids, Matthew S.
    Fisher, David C.
    Jacobsen, Eric D.
    Kim, Austin, I
    LaCasce, Ann S.
    Ng, Samuel
    Odejide, Oreofe O.
    Parry, Erin Michelle
    Isufi, Iris
    Kline, Justin
    Cohen, Jonathon B.
    Mehta-Shah, Neha
    Bartlett, Nancy L.
    Mei, Matthew
    Armand, Philippe
    Jacobson, Caron A.
    BLOOD, 2022, 140 : 6531 - 6533
  • [43] Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma
    Salles, Gilles
    Schuster, Stephen J.
    Dreyling, Martin H.
    Fischer, Luca
    Kuruvilla, John
    Patten, Piers E. M.
    Von Tresckow, Bastian
    Smith, Sonali M.
    Ubieto, Ana Isabel Jiminez
    Davis, Keith L.
    Anjos, Carla
    Chu, Jufen
    Zhang, Jie
    Bodoni, C. Lobetti
    Thieblemont, Catherine
    Fowler, Nathan H.
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Wang, Yucai
    Link, Brian K.
    BLOOD, 2021, 138
  • [44] Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma
    Dhillon, Sohita
    TARGETED ONCOLOGY, 2017, 12 (02) : 255 - 262
  • [45] Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
    Salles, Gilles
    Schuster, Stephen J.
    Dreyling, Martin
    Fischer, Luca
    Kuruvilla, John
    Patten, Piers E. M.
    von Tresckow, Bastian
    Smith, Sonali M.
    Jimenez-Ubieto, Ana
    Davis, Keith L.
    Anjos, Carla
    Chu, Jufen
    Zhang, Jie
    Bodoni, Chiara Lobetti
    Thieblemont, Catherine
    Fowler, Nathan H.
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Wang, Yucai
    Link, Brian K.
    BLOOD ADVANCES, 2022, 6 (22) : 5835 - 5843
  • [46] Clinical Use of Emerging Therapies in Relapsed or Refractory Follicular Lymphoma
    Leslie, Lori A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (12) : 15 - 19
  • [47] Translational insights into the genetics and immunobiology of relapsed/ refractory follicular lymphoma
    Yaniv, Benyamin
    Tanenbaum, Benjamin
    Kazakova, Vera
    Patel, Shyam A.
    LEUKEMIA RESEARCH, 2024, 142
  • [48] Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma
    Sohita Dhillon
    Targeted Oncology, 2017, 12 : 255 - 262
  • [49] Refining the Management of Relapsed or Refractory Follicular Lymphoma: Case Scenarios
    Pagel, John M.
    Burke, John M.
    Leslie, Lori A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (12) : 20 - +
  • [50] Allogeneic BMT/PBSCT in patients with relapsed or refractory leukemia and lymphoma. A single institution experience.
    Kirsten, D
    Blau, IW
    Basara, N
    Rudolphi, M
    Bischoff, M
    Roemer, E
    Fauser, AA
    BONE MARROW TRANSPLANTATION, 1998, 21 : S38 - S38
12345